Blood – Talk Bio

Actionable Insights Powered by AI

Novo Nordisk Acquires Rights to Omeros’ MASP-3 Inhibitor Zaltenibart

Novo Nordisk; Omeros; Zaltenibart; MASP-3 Inhibitor; Rare Blood and Kidney Disorders